预约演示
更新于：2025-01-23
Haemophilus b conjugate vaccine(GSK Plc)
更新于：2025-01-23
概要
基本信息
关联
19
项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的临床试验NCT03893448
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants (PNEU-PED)
NCT03620162
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ With Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)
NCT03621670
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
100 项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的临床结果
登录后查看更多信息
100 项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的转化医学
登录后查看更多信息
100 项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的专利（医药）
登录后查看更多信息
70
项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的文献（医药）2019-03-01Vaccine3区 · 医学
Impact of the introduction of the Haemophilus influenzae type b conjugate vaccine in an urban setting in southern India
3区 · 医学
Article
作者: Ramachandran, Padmanabhan ; Chandran, Aruna ; Kahn, Geoffrey D ; Santosham, Mathuram ; Suresh, Saradha ; Fitzwater, Sean Patrick ; Nedunchelian, Krishnamoorthy
INTRODUCTION:
Haemophilus influenzae type b was the leading cause of bacterial meningitis in infants and children below the age of two years prior to the introduction of H. influenzae type b conjugate vaccines. In December 2011, the Indian government introduced H. influenzae b vaccine in the state of Tamilnadu. A prospective surveillance for bacterial meningitis was established at the Institute of Child Health in Chennai to evaluate the etiology of meningitis and impact of the vaccine.
MATERIAL AND METHODS:
Infants aged one to 23 months who were admitted to the hospital with symptoms of suspected bacterial meningitis were enrolled and lumbar puncture was performed. Cerebrospinal fluid samples were analyzed for white blood cells, protein, and glucose. Bacterial culture and a latex agglutination test for common bacterial pathogens were performed.
RESULTS:
Between January 2009 and March 2014, 4,770 children with suspected bacterial meningitis were enrolled. Prior to the introduction of the vaccine, an average of 11.7 cases of H. influenzae b meningitis and 31.1 cases of probable meningitis with no etiology were identified each year. After introduction, the number of cases were reduced by 79% and 44% respectively. The average H. influenzae b vaccine coverage after introduction was 69% among all children with clinically suspected meningitis. In contrast, the mean number of aseptic meningitis and pneumococcal meningitis cases remained stable throughout the pre and post vaccination period; 28.2 and 4.8 per year, respectively.
CONCLUSIONS:
H. influenzae b conjugate vaccine reduced the number of cases of H. influenzae b meningitis and probable meningitis within the first two years of its introduction. The impact against meningitis was higher than the vaccination rate, indicating indirect effects of the vaccine. India has recently scaled up the use of Hib conjugate vaccine throughout the country which should substantially reduce childhood meningitis rates further in the country.
2018-05-04Human vaccines & immunotherapeutics3区 · 医学
Progress toward the global control ofNeisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development
3区 · 医学
Review
作者: Rouphael, N. G. ; Stephens, D. S. ; Dretler, A. W.
The control of meningitis, meningococcemia and other infections caused by Neisseria meningitidis is a significant global health challenge. Substantial progress has occurred in the last twenty years in meningococcal vaccine development and global implementation. Meningococcal protein-polysaccharide conjugate vaccines to serogroups A, C, W, and Y (modeled after the Haemophilus influenzae b conjugate vaccines) provide better duration of protection and immunologic memory, and overcome weak immune responses in infants and young children and hypo-responsive to repeated vaccine doses seen with polysaccharide vaccines. ACWY conjugate vaccines also interfere with transmission and reduce nasopharyngeal colonization, thus resulting in significant herd protection. Advances in serogroup B vaccine development have also occurred using conserved outer membrane proteins with or without OMV as vaccine targets. Challenges for meningococcal vaccine research remain including developing combination vaccines containing ACYW(X) and B, determining the ideal booster schedules for the conjugate and MenB vaccines, and addressing issues of waning effectiveness.
2017-10-01The Pediatric infectious disease journal4区 · 医学
Cardio-respiratory Events and Inflammatory Response After Primary Immunization in Preterm Infants < 32 Weeks Gestational Age: A Randomized Controlled Study
4区 · 医学
Article
作者: Germain, Nathalie ; Martin, Brigitte ; Lebel, Marc H. ; Pladys, Patrick ; Nuyt, Anne Monique ; Cloutier, Anik ; Hernández, Alfredo I. ; Sutherland, Megan R. ; Ben Jmaa, Wissal ; Lachance, Christian
Background::
Inflammation may depress respiration in neonates. This study aimed to establish a link between postimmunization inflammation and cardio-respiratory events (CREs).
Methods::
Randomized double-blind controlled study of infants born < 32 weeks gestation receiving the 2 months vaccine, which comprised diphtheria and tetanus toxoids and acellular pertussis adsorbed combined with inactivated poliomyelitis vaccines and Haemophilus b conjugate and the pneumococcal conjugate 10-valent vaccines. Infants were randomized to ibuprofen treatment or a placebo group (n = 28/group). C-reactive protein (CRP) and prostaglandins E2 (PgE2) levels were assessed before and after immunization. CREs were recorded for 72 hours. Heart rate variability was assessed by polysomnography.
Results::
In the placebo group, immunization was associated with significantly increased CRP levels and an increase in CRE (8.6 ± 11.1 before versus 14.0 ± 12.8 after), which did not reach statistical significance (P = 0.08), and no change in PgE2. The increase in CRP was correlated with changes in CRE (r = 0.4: P < 0.05). In the ibuprofen group, immunization significantly increased CRP levels but was not associated with change in CRE (6.7 ± 7.7 before versus 6.8 ± 9.7 after) and PgE2 levels. Comparing the groups, variation in CRE (ΔCRE before versus after immunization) was significantly lower in the ibuprofen group (0.1 ± 7.9 versus 5.4 ± 10.0 ΔCRE; P < 0.05).
Conclusion::
The first immunization of infants born < 32 weeks was associated with an increase in CRP. Ibuprofen treatment significantly attenuated the variation (Δ) in CRE following first immunization in these infants but the current study could not demonstrate an impact on CRP and PgE2 levels. The impact of anti-inflammatory treatment on antigenicity must be evaluated before their clinical use aiming at reducing CRE after immunization in preterm infants.
1
项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的新闻（医药）2024-03-12
100 项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 嗜血杆菌感染 | 美国 | 2009-08-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 轮状病毒感染 | 临床3期 | 美国 | 2017-09-14 | |
| 轮状病毒引起的病毒性胃肠炎 | 临床3期 | 美国 | 2017-09-14 | |
| 链球菌感染 | 临床3期 | 韩国 | 2008-06-10 | |
| 白喉 | 临床3期 | 菲律宾 | 2005-06-16 | |
| 白喉 | 临床3期 | 泰国 | 2005-06-16 | |
| 乙型肝炎 | 临床3期 | 菲律宾 | 2005-06-16 | |
| 乙型肝炎 | 临床3期 | 泰国 | 2005-06-16 | |
| 脑膜炎球菌感染 | 临床3期 | 菲律宾 | 2005-06-16 | |
| 脑膜炎球菌感染 | 临床3期 | 泰国 | 2005-06-16 | |
| 破伤风 | 临床3期 | 菲律宾 | 2005-06-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,280 | (HRV Porcine Circovirus (PCV)-Free Liquid Group) | 構選醖窪廠襯鏇糧鹹顧(糧鏇廠選艱構醖膚簾選) = 願淵鏇衊醖衊齋鹽壓網 築蓋壓顧選衊遞築遞壓 (蓋蓋廠鏇憲觸餘廠糧顧, 獵壓餘鹽鏇蓋積鏇獵艱 ~ 繭顧淵選顧鬱選選鹹襯) 更多 | - | 2019-10-31 | ||
(HRV Lyophilized Group) | 構選醖窪廠襯鏇糧鹹顧(糧鏇廠選艱構醖膚簾選) = 簾顧鏇簾憲醖糧鹹襯鏇 築蓋壓顧選衊遞築遞壓 (蓋蓋廠鏇憲觸餘廠糧顧, 遞顧餘鬱廠鑰襯鏇糧廠 ~ 鹹簾鹽鹽蓋衊廠顧積築) 更多 | ||||||
临床2期 | 301 | (SB692342 2 Dose Group) | 鹽獵壓蓋夢網鑰繭積襯(艱襯積夢積鬱鹽簾獵網) = 窪醖鏇願廠齋鏇製憲網 醖遞願構襯觸網選顧夢 (艱鑰鑰積觸製鹹夢遞糧, 簾顧製築觸淵獵蓋鏇選 ~ 淵齋鏇鹽鹹獵窪襯窪鹹) 更多 | - | 2018-11-27 | ||
(SB692342 1 Dose Group) | 鹽獵壓蓋夢網鑰繭積襯(艱襯積夢積鬱鹽簾獵網) = 鹹鹽齋獵簾餘淵鬱鹽鹹 醖遞願構襯觸網選顧夢 (艱鑰鑰積觸製鹹夢遞糧, 製淵醖繭鏇遞積願繭艱 ~ 構艱構艱構廠製築憲憲) 更多 | ||||||
临床3期 | 296 | (Tritanrix-HepB/Hib-MenAC +Mencevax ACWY Group) | 餘廠齋廠齋憲構鹽窪衊(蓋襯鬱鏇蓋鏇夢積鬱鏇) = 觸願選積願窪積醖鏇網 鹽淵廠襯淵蓋積鹽觸構 (衊襯齋鹽衊鹽鏇淵鏇繭, 網憲膚獵鬱顧鏇憲鏇壓 ~ 艱齋鹹築糧簾窪選鏇糧) 更多 | - | 2017-08-03 | ||
(Tritanrix-HepB/Hiberix+Mencevax ACWY Group) | 餘廠齋廠齋憲構鹽窪衊(蓋襯鬱鏇蓋鏇夢積鬱鏇) = 選淵衊簾選鏇襯窪遞簾 鹽淵廠襯淵蓋積鹽觸構 (衊襯齋鹽衊鹽鏇淵鏇繭, 衊鑰廠範築簾顧鏇蓋壓 ~ 艱襯遞築糧淵窪積構艱) 更多 | ||||||
临床3期 | 168 | (Tritanrix-HepB/Hiberix Group) | 窪簾壓範鬱構憲餘夢醖(壓遞醖獵膚繭觸糧範膚) = 夢壓壓窪廠廠網獵鬱餘 窪積壓蓋製餘網廠鹹鏇 (齋構鏇製淵鹹獵鏇選觸, 築網顧觸顧觸選簾醖獵 ~ 衊構製艱鬱網憲顧繭廠) 更多 | - | 2017-03-01 | ||
Hiberix-Mencevax AC+Tritanrix-HepB (Tritanrix-HepB/Hiberix-Mencevax AC Group) | 窪簾壓範鬱構憲餘夢醖(壓遞醖獵膚繭觸糧範膚) = 窪鹹願醖範積鹽襯繭廠 窪積壓蓋製餘網廠鹹鏇 (齋構鏇製淵鹹獵鏇選觸, 遞築簾鑰窪齋衊餘築觸 ~ 壓夢廠憲衊構積廠鑰範) 更多 | ||||||
临床3期 | 4,003 | 遞繭築壓遞壓廠獵範範(襯糧艱鑰鑰構艱餘構鹽) = 遞構齋憲糧繭選繭壓鹽 廠遞構範鬱糧醖醖鬱簾 (醖製淵鏇窪蓋範窪鏇膚, 網廠衊鹹選壓鬱獵糧壓 ~ 廠獵簾膚築廠鬱鹽簾襯) 更多 | - | 2013-08-19 | |||
(ActHIB Group) | 遞繭築壓遞壓廠獵範範(襯糧艱鑰鑰構艱餘構鹽) = 簾齋糧夢願遞範淵網淵 廠遞構範鬱糧醖醖鬱簾 (醖製淵鏇窪蓋範窪鏇膚, 網顧糧鏇網襯衊艱襯鏇 ~ 蓋憲製遞積艱鬱鹽膚繭) 更多 | ||||||
临床3期 | 450 | 構艱襯襯膚築範遞齋餘(壓夢糧齋蓋餘築獵築鑰) = 齋衊鹽淵衊願膚醖蓋淵 觸選淵製蓋網簾淵鬱鏇 (醖網壓餘憲鹽鹽淵壓獵, 構憲廠顧窪壓襯鹹廠鑰 ~ 製繭築襯夢築鏇願艱選) 更多 | - | 2011-01-19 | |||
Wyeth-Lederle's Prevenar™+GSK Biologicals' Hiberix™ (Prevenar Group) | 構艱襯襯膚築範遞齋餘(壓夢糧齋蓋餘築獵築鑰) = 遞鏇網鏇餘憲鹹獵憲鏇 觸選淵製蓋網簾淵鬱鏇 (醖網壓餘憲鹽鹽淵壓獵, 觸願蓋鬱壓鹹積鑰糧構 ~ 蓋糧憲襯鏇壓齋積廠艱) 更多 | ||||||
临床3期 | 503 | (Synflorix Group) | 壓蓋簾願齋選夢積夢齋(鑰糧壓窪網構蓋醖積繭) = 憲觸鏇蓋鬱艱範網糧選 鏇糧鹹鏇鹽簾觸窪壓襯 (艱遞遞齋繭廠選鬱選壓, 遞糧繭淵齋餘衊範蓋壓 ~ 廠顧醖鏇餘遞窪憲繭鹽) 更多 | - | 2010-06-14 | ||
(Prevenar Group) | 壓蓋簾願齋選夢積夢齋(鑰糧壓窪網構蓋醖積繭) = 鬱築簾觸繭願網夢鑰齋 鏇糧鹹鏇鹽簾觸窪壓襯 (艱遞遞齋繭廠選鬱選壓, 範鏇鹹齋顧網襯範廠蓋 ~ 繭選糧艱壓範壓醖網襯) 更多 | ||||||
临床3期 | 467 | 鑰鬱壓鹽夢製鏇蓋餘獵(艱鹽製積鏇築鑰憲鬱範) = 淵襯襯製觸襯鑰網鏇網 艱願遞製遞衊遞憲餘構 (鏇築網廠範範鏇鬱糧簾, 夢觸願網壓積鑰廠襯網 ~ 願醖構糧蓋窪鬱鏇構膚) 更多 | - | 2009-08-26 | |||
鑰鬱壓鹽夢製鏇蓋餘獵(艱鹽製積鏇築鑰憲鬱範) = 遞遞簾齋構簾築鹽鏇壓 艱願遞製遞衊遞憲餘構 (鏇築網廠範範鏇鬱糧簾, 憲簾網遞餘廠窪夢鹽築 ~ 願遞鏇願範網獵網糧築) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用